The company's latest quarterly earnings report is scheduled for Monday, May 4th, with a consensus estimate EPS of 2.83.
IQVIA Holdings Inc. (IQV) is currently priced at $161.44, experiencing a price decrease of $2.4 (-1.46%) from the previous close. The trading volume stands at $231,556, representing a 10.83% increase relative to the average.
The most recent quarterly earnings report was on Wednesday, February 4th, with a consensus estimate EPS of 3.4. The company reported a net income of $514 million.
The company's operating cash flow is $735 million, resulting in a net change in cash of $166 million. IQV ended the period with $1.98 billion in cash.
IQVIA's revenue for the period is $4.36 billion, generating a gross profit of $292 million. The company reported an EPS of $3.02 and a net income of $514 million.
Some key ratios include a net profit margin of 11.78%, return on equity of 7.9, and a price-to-earnings ratio of 18.64.
As per the balance sheet, IQV has total assets of $29.94 billion, total liabilities of $23.31 billion, and net debt of $14.19 billion.
This real-time financial report provides insights into IQVIA Holdings Inc.'s current financial status and performance metrics.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.